pehub.com -- Novast Pharmaceuticals Ltd., a Chinese generic pharmaceutical maker, has raised $25 million in Series C funding, according to VentureWire. SAIF Partners led the round, and was joined by return backers New Enterprise Associates, Qiming Ventures, Eli Lilly & Co. and BioVeda Capital. Novast does not have a website.
